Article Text

Download PDFPDF

Original research
Intrathrombus polymer coating deposition: a pilot study of 91 patients undergoing endovascular therapy for acute large vessel stroke. Part I: Histologic frequency
  1. Rashi I Mehta1,
  2. Ansaar T Rai2,
  3. Jeffrey A Vos3,
  4. Orestes E Solis4,
  5. Rupal I Mehta4,5
  1. 1 Department of Radiology, West Virginia University, Morgantown, West Virginia, USA
  2. 2 Department of Neurointerventional Radiology, West Virginia University, Morgantown, West Virginia, USA
  3. 3 Department of Pathology, West Virginia University, Morgantown, West Virginia, USA
  4. 4 Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
  5. 5 Department of Neuroscience, University of Rochester, Rochester, NY, USA
  1. Correspondence to Dr Rashi I Mehta, Department of Radiology, West Virginia University, Morgantown, WV 26505, USA; rashi.mehta{at}hsc.wvu.edu

Abstract

Background Polymer coating embolism due to vascular medical device use is an increasingly recognized iatrogenic complication. This phenomenon has been linked with various adverse effects including neuroinflammation, acute ischemic stroke, cerebral hemorrhage, and death. Notably, procedure- and device-specific risks of this complication are poorly investigated. In this study, we evaluate the detectable frequency of intra-arterial polymer coating delamination among patients who underwent endovascular thrombectomy for treatment of acute ischemic stroke due to large vessel occlusion.

Methods Ninety-two cerebral thrombectomy specimens were retrospectively analyzed for the presence of polymer coating particulates. Histologic findings were correlated with demographic and procedural details and patient outcomes.

Results Evidence of polymer coating deposition was found in 30 of 92 extracted thrombi (33%). No correlation between intrathrombus polymer deposition and use of a specific thrombectomy device such as a stent retriever, aspiration catheter, or guide catheter was found. However, heterogeneous patterns of device use suggest a number of culprit devices. A trend toward longer procedure times and multiple thrombectomy passes was noted in positive cases. Intrathrombus polymer deposition was not associated with adverse clinical outcomes as measured by the 90-day modified Rankin Scale (mRS); however, small sample size and follow-up intervals limit interpretation. Ninety-day outcomes based on mRS may not fully capture the clinical effects of acute and/or delayed intracerebral polymer complications.

Conclusion In light of documented adverse neurologic effects, the frequency of intrathrombus polymer particulates indicates the need for consensus testing methods and large-scale long-term prospective clinical device trials, with inclusion of relevant endpoints to better assess biomaterial and device risks to patients.

  • complication
  • device
  • stroke
  • angiography
  • thrombectomy

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors RIM, RIM: Study design and conception, data collection, data analysis, manuscript preparation, approval of final version of the manuscript. ATR: Study design, data collection, data analysis, approval of final version of the manuscript. JAV, OES: Data collection, data analysis, approval of final version of the manuscript.

  • Funding RIM (Rashi I Mehta) is supported by a grant from the National Institute of General Medical Sciences of the National Institutes of Health (5U54GM104942-03). RIM (Rupal I Mehta) is supported by a grant from the National Institute of Neurological Disorders and Stroke (K08NS089830).

  • Competing interests ATR serves as a consultant for Stryker Corporation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Presented at This work was presented at the SNIS 15th Annual Meeting San Francisco, California, USA.

  • Patient consent for publication Not required.